COVID-19: Seaweed slimy ingredient: High inhibitory activity on the new corona.
-“Fucoidan” is a candidate for antiviral drug-
Keio University
Fucoidan, a sulfated polysaccharide that is a slimy component of seaweed
“Fucoidan” has been confirmed to have high inhibitory activity against the new coronavirus.
Joint research with Osaka University:
Systematic organic synthesis of sulfated tetrasaccharide, which is the basis of fucoidan.
“Evaluation of binding to spike protein” of the new corona was carried out.
A “sulfation pattern that easily binds to spike proteins” was found.
This will lead to the development of candidate substances for antiviral drugs and virus adsorption masks.
Natural Fucoidan:
Inhibitory activity on the new corona has been reported.
However,
Because it is a mixture of different structures
Which structure of polysaccharide is working
Until now, I didn’t know.
Assessing inhibitory activity:
Therefore, 12 types of tetrasaccharides with precisely controlled sulfated sites were synthesized.
Then, the inhibitory activity of spike protein was evaluated.
Evaluation result:
resulting in,
With a structure in which nine hydroxyl groups were sulfated, high inhibitory activity was obtained.
Inhibition constant is 3 micromolar concentration (micro is one millionth)
6 micro-10 micromolar concentration for protein variants.
It was also confirmed that “there is no inhibitory effect on the blood coagulation factor FXa”.
Fucoidan:
Anti-cancer and antibacterial effects have been reported.
However, it is difficult to use natural fucoidan as a medicine.
Precisely synthesize
Sulfated tetrasaccharide with a clear molecular structure,
If you can identify the site of antiviral action,
It can be a candidate substance for pharmaceutical products.
Keio Techno Mall 2021:
Keio University will announce on December 10th at the online “22nd Keio Science and Technology Exhibition” (Keio Techno Mall 2021).
New switch
Kyushu University, with ACE2 by seaweed component
Confirmed inhibition of spike protein binding
FCC Horiuchi Press Release
https://kyodonewsprwire.jp/release/202102191238
Influenza | Fucoidan Evidence